Answers are grounded in this paper and cite their sources.
Engineered bacteria are developing rapidly and hold promise as programmable platforms for biosynthesis, environmental sensing, disease diagnosis, drug delivery and cancer therapy. However, the thematic structure of this expanding literature remains difficult to interpret through conventional narrative summaries alone. Here, we performed a Web of Science Core Collection-based bibliometric and topic-network analysis of engineered-bacteria publications from 1 January 2015 to 14 August 2025. Co-occurrence clustering divided global research topics into five major clusters, among which drug delivery, and cancer therapy formed a recent translationally oriented cluster. Time-series analysis, keyword regression, and burst analysis suggested that probiotic engineering, microbiota-related research, therapy, and drug delivery are topics of growing research interest, whereas engineered probiotics, tumor biology, and the tumor microenvironment represent candidate emerging topics. Walktrap community detection further highlighted tumor-related engineered-bacteria research as a field-connected area that warrants closer mechanistic and translational synthesis. These findings should be interpreted as exploratory bibliometric signals derived from a single curated database rather than direct evidence of clinical feasibility. This study maps the current knowledge structure of engineered-bacteria research and supports drug delivery and cancer therapy as important directions for future experimental and translational work.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: